Across 3 studies, all reported beneficial effects of Lactobacillus brevis SBC8803 on liver function, with effect sizes ranging from small to moderate. The evidence comes from review articles and an animal model; no data on dose, duration, form, or human-specific populations were available. Given the small number of studies and lack of statistical significance data, the findings should be considered preliminary.
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. All studies are either reviews or an animal model; no human clinical trials with direct dosing or statistical significance are available. The third study used a different Lactobacillus species (L. fermentum LA12), not Lactobacillus brevis SBC8803, reducing direct applicability. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed).
This review analyzes the effects of gut microbiome modulation on the course of CLD, by using pharmacotherapy, nutrition, fecal microbiota transplantation, supplements, and probiotics.
probiotic therapy as a safe, inexpensive and a noninvasive strategy can reduce pathophysiological symptoms and improve different types of liver diseases without side effects
Serum and hepatic analyses also revealed that the restoration of epithelial barrier function may prevent the leakage of endotoxin into the blood, subsequently improve liver function and hepatic steatosis in the L. fermentum LA12-treated rats.